Exco InTouch Achieve a New First in Mobile Clinical Technology - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Exco InTouch Achieve a New First in Mobile Clinical Technology

Source: Company News Release
Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers today announced a new first in the clinical technology arena. Having pioneered the use of mobile technology, increasing retention and compliance through engaging and supporting patients, and facilitating the delivery of ePRO via mobile devices, the forward looking company are now the only electronic Clinical Outcomes Assessment (eCOA) provider to have published public-facing apps on all three mobile operating platforms (iOS, Android and Windows8).

Dale Jessop, CTO at Exco InTouch, commented: “We’re thrilled to have reached this milestone, and even more so having used native apps, as this provides the user with device specific natural controls - driving familiarity and ease of use. Currently the most common approach is to use HTML5, which wraps a web app into mobile operating controls, however, this does not enable the layout to be optimized for the device in use, or incorporate natural button configurations and so does not present the best experience for patients. In contrast, our pedigree in developing mobile solutions for clinical and healthcare programs has enabled us to deliver the benefits of native apps in a timely, cost effective manner across all platforms.”

The variety of apps developed for clients by Exco InTouch covers a broad range of therapeutic areas; from cardiovascular and respiratory diseases through to smoking cessation and vaccination programs, utilizing their flexible platform which adapts to individual program needs. The platform enables the integration of medical device data and also lifestyle devices, such as FitBit™, which are increasingly popular in clinical research to provide secondary outcomes data.

The company’s leading approach enables its clients to select their preferred delivery model, offering the flexibility to either provision appropriate devices for the study population, or more significantly to enable BYOD (Bring Your Own Device) in both clinical and commercial programs. This is enabled by proprietary mDNA® technology, which provides sponsors and payers the robust reassurance of protecting Personally Identifiable Information (PII) and maintaining data security even when using the patients’ own devices.

Tim Davis, CEO and founder of Exco InTouch, commented: “We are leading the way in delivering native apps across all three mobile operating platforms, which not only is an achievement for our company, but also another great milestone for the entire clinical industry. There is huge demand in the industry for eCOA providers to deliver user friendly solutions that the patient finds easy to use and accessible. A clinical trial is reliant on timely engagement from its patients and we are delighted to be foremost in improving patients’ user experience.”

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here